Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The interesting thing about the PTSC PR versus the TPL PR is the obvious change.

Also, it could it be percieved that TPL uses that language to intimidate infringers to license, but PTSC would use it to gain investors. Not necessarily the case, but if things did not pan out TPL has nothing to lose, but PTSC may have SEC issues to deal with. Let TPL put out those kind of stronger PRs, and have us more safely benefit.

Share
New Message
Please login to post a reply